Daraxonrasib Approved for Metastatic Pancreatic Cancer

On August 26 2026, the United States Food and Drug Administration (US FDA) approved daraxonrasib for the treatment of pancreatic cancer. The drug is designed to be used as a form of targeted therapy for patients with advanced pancreatic cancer.

One of the most common mutations linked to pancreatic cancer is KRAS (Kirsten rat sarcoma virus oncogene homologue). KRAS is a form of RAS mutation found in over 90% of all pancreatic cancer cases. The RAS protein is responsible for cell division and growth and mutations to the protein result in uncontrolled cell growth, contributing to the development of cancer cells.

Rasonque (daraxonrasib), produced by Revolution Medicines, is an oral tablet meant to be taken once daily. It is a RAS inhibitor, targeting multiple different forms of the RAS protein. It is currently approved for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

In April 2026, Revolution Medicines announced the preliminary findings of a phase 3 clinical trial on daraxonrasib, highlighting the potential of the drug in increasing the survival rates of patients diagnosed with metastatic pancreatic ductal adenocarcinoma.

The next month, they presented the findings of their trial at the American Society for Clinical Oncology (ASCO) annual meeting in Chicago. The drug also received permission by the US FDA for an expanded access protocol (EAP). This allowed patients with serious disease to gain access to the drug without enrolling in a clinical trial.

In July 2026, the company filed for a New Drug Application (NDA), which was officially accepted by the US FDA for priority review. Now, the drug is approved by the FDA, months ahead of schedule.

“Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer. It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible. I am immensely proud of the dedicated FDA scientists whose fast, thorough review and relentless commitment made this groundbreaking milestone a reality,” Acting FDA Commissioner Kyle Diamantas, J.D. shared.

Pancreatic cancer remains one of the deadliest forms of cancer, with an overall five-year survival rate of 13%. It is also the sixth leading cause of cancer-related deaths and accounts for 3% of all cancers in the US. Being aware of the common signs and symptoms is crucial for early detection and a more favourable prognosis.